[
  {
    "ts": null,
    "headline": "AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients",
    "summary": "AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental health impacts of a chronic lymphocytic leukemia (CLL) diagnosis. Findings from the survey are the first to report the emotional perspectives of Hispanic, Black, and Asian patients with CLL and their unique experiences and challenges throughout their blood cancer journey.3 The findings were shared during the 66th American Society of Hematology",
    "url": "https://finnhub.io/api/news?id=bc8fbb207e43c5bdcfe6f4af28d2e961a5eebcaba28a5483b134382d6b961cea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733688000,
      "headline": "AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients",
      "id": 131866859,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental health impacts of a chronic lymphocytic leukemia (CLL) diagnosis. Findings from the survey are the first to report the emotional perspectives of Hispanic, Black, and Asian patients with CLL and their unique experiences and challenges throughout their blood cancer journey.3 The findings were shared during the 66th American Society of Hematology",
      "url": "https://finnhub.io/api/news?id=bc8fbb207e43c5bdcfe6f4af28d2e961a5eebcaba28a5483b134382d6b961cea"
    }
  },
  {
    "ts": null,
    "headline": "Investigational Epcoritamab (DuoBody速 CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)",
    "summary": "AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b/2 EPCORE速 NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide + rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). Among 111 patients with a median follow-up of over two years, overall response rate (ORR) was 96%, and complete response (CR) rate was 87%. The data (Abstract #342)",
    "url": "https://finnhub.io/api/news?id=dd61d099788e0fb017690ce0c66362edbdb6a926c2009e23cacafe679440a38c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733616000,
      "headline": "Investigational Epcoritamab (DuoBody速 CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)",
      "id": 131853730,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b/2 EPCORE速 NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide + rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). Among 111 patients with a median follow-up of over two years, overall response rate (ORR) was 96%, and complete response (CR) rate was 87%. The data (Abstract #342)",
      "url": "https://finnhub.io/api/news?id=dd61d099788e0fb017690ce0c66362edbdb6a926c2009e23cacafe679440a38c"
    }
  }
]